AN2 Therapeutics, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission (SEC) at 12:31 UTC on Monday, 9 November 2026. The filing reports Item 2.02, Results of Operations and Financial Condition.
A Form 8-K is the report U.S. public companies file to tell investors about significant events between their regular quarterly and annual reports. Each item in the form covers one type of event.
The accompanying press release (Exhibit 99.1) opens: Global Phase 2 study of oral epetraborole in polycythemia vera (PV) cleared to proceed in all planned jurisdictions; expect to initiate enrollment by year-end
The filing also lists Item 9.01, Financial Statements and Exhibits.
Source: U.S. Securities and Exchange Commission (EDGAR) filing